Immuneering Corporation (IMRX) — Stock Valuation & Research

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes…

IMRX key statistics

Price$3.65
Market cap$236.46M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range3.38-8.48
Beta0.39

Explore IMRX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.